TEVA Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
Company profile
Ticker
TEVA
Exchange
Website
CEO
Kaare Schultz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott • Abbvie ...
Former names
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SEC CIK
Corporate docs
TEVA stock data
()
News
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
16 Apr 21
UK Trial On Mix-Match COVID-19 Vaccines Expanded To Add Moderna, Novavax Shots
14 Apr 21
South African Variant Able To Elude Pfizer/BioNTech' Vaccine Protection, Israeli Study Shows: Report
12 Apr 21
Government, Officials Defend AstraZeneca's COVID-19 Shot: CNBC
8 Apr 21
Teva Canada Announces New Autoinjector for AJOVY for the Preventive Treatment of Migraine in Adults
8 Apr 21
Press releases
Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 28, 2021
6 Apr 21
Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, used to treat high pressure inside the eye, in the United States
8 Mar 21
Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference
1 Mar 21
New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments
26 Feb 21
Teva Reports Fourth Quarter and Full Year 2020 Financial Results
10 Feb 21
Calendar
10 Feb 21
18 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.18B | 2.18B | 2.18B | 2.18B | 2.18B | 2.18B |
Cash burn (monthly) | (positive/no burn) | (positive/no burn) | (positive/no burn) | 297.67M | (positive/no burn) | (positive/no burn) |
Cash used (since last report) | n/a | n/a | n/a | 1.07B | n/a | n/a |
Cash remaining | n/a | n/a | n/a | 1.1B | n/a | n/a |
Runway (months of cash) | n/a | n/a | n/a | 3.7 | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Mar 21 | Mark Sabag | Ordinary Shares | Sell | Dispose S | No | No | 11.2195 | 127,244 | 1.43M | 20,598 |
5 Mar 21 | Eliyahu Sharon Kalif | Restricted Share Units Ordinary Shares | Grant | Aquire A | No | No | 0 | 85,551 | 0 | 85,551 |
5 Mar 21 | Sven Dethlefs | Restricted Share Units Ordinary Shares | Grant | Aquire A | No | No | 0 | 99,809 | 0 | 99,809 |
5 Mar 21 | Richard Daniell | Restricted Share Units Ordinary Shares | Grant | Aquire A | No | No | 0 | 90,304 | 0 | 90,304 |
5 Mar 21 | Eric Drape | Restricted Share Units Ordinary Shares | Grant | Aquire A | No | No | 0 | 90,304 | 0 | 90,304 |
4 Mar 21 | Sven Dethlefs | Ordinary Shares | Sell | Dispose S | No | Yes | 10.5661 | 6,012 | 63.52K | 77,975.7 |
4 Mar 21 | Sven Dethlefs | Ordinary Shares | Option exercise | Aquire M | No | No | 0 | 13,930 | 0 | 83,987.7 |
4 Mar 21 | Sven Dethlefs | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 13,930 | 0 | 27,861 |
4 Mar 21 | Richard Daniell | Ordinary Shares | Sell | Dispose S | No | Yes | 10.5844 | 7,513 | 79.52K | 20,280 |
4 Mar 21 | Richard Daniell | Ordinary Shares | Option exercise | Aquire M | No | No | 0 | 15,920 | 0 | 27,793 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
11.9% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 2 |
Opened positions | 2 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 1.26B |
Total shares | 130.45M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|---|---|
Capital Research Global Investors | 130.14M | $1.26B |
Wellington Management | 310.79K | $3M |
Financial report summary
?Competition
Akorn • Teligent • Spectrum Pharmaceuticals • Actavis • Nektar Therapeutics • Neurocrine Biosciences • Acorda Therapeutics • Innoviva • NeuBase Therapeutics • Amphastar PharmaceuticalsManagement Discussion
- The discussion that follows includes a comparison of our results of operations and liquidity and capital resources for fiscal years 2020 and 2019. For a comparison of our results of operations and financial condition for fiscal years 2019 and 2018, see “Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2019 Annual Report on Form10-K,
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
adalimumab, adapt, adapting, African, ago, agreemen, albeit, Alvotech, amplified, Anfinitor, Apixaban, AptensioXR, argument, arm, Ascorbate, Ascorbic, Asian, aspire, Atripla, BCBSM, bellwether, Biden, Brazilian, busin, Bystolic, Cal, capture, Carbamazepine, CAUTIONARY, CECL, celebrate, cerebral, Chloride, chose, circumscribed, Clotrimazole, communicable, conscientiously, conviction, curb, dance, debarment, deceleration, dermatological, detriment, diagnosed, Dimethyl, disciplined, distancing, distinguish, dominant, DSCSA, durability, duringthese, economy, EEA, Efavirenz, Eliquisr, email, emotional, emtricitabine, ensuing, ESG, ess, Etodolac, exclusionary, fear, feel, feeling, female, fifty, Francisco, Goa, guiding, healthy, hesitancy, Humira, hygiene, IFR, Ill, Imiquimod, immunogenicity, imperative, impleme, indicted, indictment, inMarch, inside, irbesartan, issubject, jurisdiction, krona, LAI, learning, lifetime, Lisbon, losartan, mapping, MDI, men, mentoring, MFN, midst, morale, MoviPrep, Nadolol, nebivolol, NOC, nted, numerical, ofproperty, Ointment, online, outbreak, outreach, Pa, palsy, pandemic, PhRMA, play, pleading, pled, PM, postponed, PPE, precautionary, preemption, pride, protectionist, prove, proximity, PSUsgranted, purity, quota, ranitidine, recession, reconsider, redundancy, reinstated, relaunch, reluctance, remotely, repose, resonating, risperidone, Romidepsin, safeguarding, schizophrenia, sending, shape, show, showed, skinny, slower, society, statistical, steeper, strained, Subtopic, survey, survive, Swedish, swelled, tamper, Te, Temozolomide, temporarily, thecourt, Theexpense, theirperformance, thesale, thoughtful, tirelessly, toBB, Tobramycin, toresidual, town, traceability, Truvada, turnover, underscore, uninterrupted, unprecedented, upholding, Upjohn, upper, uptake, upto, va, Virgin, virtual, virtually, Warfarin, wave, week, wellbeing, workplace, Zyclara
Removed:
abolishment, actuated, addressed, ADHD, Advair, Aggrenox, Amazon, AmerisourceBergen, announcement, annum, anticompetitive, AOP, appointed, asqui, assured, attempting, Baker, Barr, Barry, BBB, begun, bench, benralizumab, benzoyl, Berkshire, beta, BI, blocking, Boehringer, breath, CAD, cancer, capitalize, capped, Chase, chemotherapy, CHF, children, ciclesonide, cluster, Concerta, conclusion, confirmed, conform, consisting, constant, creditable, declare, declared, declined, deconsolidated, deconsolidation, deem, deliberately, denying, departure, derivatively, devaluation, diligence, dilutive, divert, docket, DuoResp, eleven, Elliot, ELS, episodic, EUR, expanded, exposing, Flovent, Frazer, GBP, gradual, grantor, Grodko, guanfacine, Hathaway, hinder, hip, hydrofluoroalkane, identification, impair, ineffectively, influenced, Ingelheim, insured, Integrating, intensified, interfere, intervene, Intuniv, invalidating, invoiced, irrespective, ixazomib, join, JPMorgan, JPY, Kabi, knee, LABA, language, leasing, levalbuterol, lobby, losing, low, lung, Lupin, matured, McKesson, mesalamine, Modernization, mono, month, Ninlaro, Nordic, opted, ordered, originate, OZ, perception, permanent, permission, permitted, peroxide, Perrigo, persuade, persuasive, pharmacovigilance, PLN, preclude, presiding, prevented, prioritize, punitive, quantification, question, realizing, refundable, rejected, relator, reliably, relocation, remained, repeal, replace, resale, responding, restoring, retroactive, retrospectively, revealed, reverse, saleable, Shire, situated, Slayback, smooth, speaker, stabilizing, substantive, suffered, tam, TD, topical, translate, traumatic, TriCor, underpinning, undo, Unfair, unforeseen, unsealed, USP, utilization, variability, Venezuela, Venezuelan, vi, voluntarily, warehousing, warranty, whistleblower, Wisconsin, withheld, worsen
Financial reports
10-K
2020 FY
Annual report
10 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
21 Feb 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19
10-K
2018 FY
Annual report
19 Feb 19
10-Q
2018 Q3
Quarterly report
1 Nov 18
Current reports
8-K
Results of Operations and Financial Condition
10 Feb 21
8-K
Departure of Directors or Certain Officers
2 Feb 21
8-K
Departure of Directors or Certain Officers
25 Jan 21
8-K
Results of Operations and Financial Condition
5 Nov 20
8-K
Departure of Directors or Certain Officers
6 Aug 20
8-K
Results of Operations and Financial Condition
5 Aug 20
8-K
Departure of Directors or Certain Officers
9 Jun 20
8-K
Results of Operations and Financial Condition
7 May 20
8-K
Results of Operations and Financial Condition
12 Feb 20
8-K
Entry into a Material Definitive Agreement
25 Nov 19
Registration and prospectus
424B3
Prospectus supplement
17 Aug 20
S-4
Registration of securities issued in business combination transactions
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8
Registration of securities for employees
5 Aug 20
F-6
Registration for ADRs (foreign)
13 Nov 18
424B3
Prospectus supplement
18 Apr 18
Proxies
DEFA14A
Additional proxy soliciting materials
26 May 20
DEFA14A
Additional proxy soliciting materials
22 Apr 20
DEF 14A
Definitive proxy
22 Apr 20
PRE 14A
Preliminary proxy
19 Mar 20
DEFA14A
Additional proxy soliciting materials
16 Apr 19
DEF 14A
Definitive proxy
16 Apr 19
DEF 14A
Definitive proxy
24 Apr 18
DEFA14A
Additional proxy soliciting materials
24 Apr 18
Other
EFFECT
Notice of effectiveness
18 Aug 20
SD
Conflict minerals disclosure
14 Aug 20
CORRESP
Correspondence with SEC
12 Aug 20
CORRESP
Correspondence with SEC
12 Aug 20
UPLOAD
Letter from SEC
10 Aug 20
UPLOAD
Letter from SEC
14 Jul 20
CORRESP
Correspondence with SEC
18 Jun 20
CORRESP
Correspondence with SEC
16 Apr 20
SD
Conflict minerals disclosure
31 May 19
EFFECT
Notice of effectiveness
4 Dec 18
Ownership
4
TEVA PHARMACEUTICAL INDUSTRIES / Mark Sabag ownership change
17 Mar 21
4
TEVA PHARMACEUTICAL INDUSTRIES / David Matthew Stark ownership change
8 Mar 21
4
TEVA PHARMACEUTICAL INDUSTRIES / Kare Schultz ownership change
8 Mar 21
4
TEVA PHARMACEUTICAL INDUSTRIES / Mark Sabag ownership change
8 Mar 21
4
TEVA PHARMACEUTICAL INDUSTRIES / Brendan P. O'Grady ownership change
8 Mar 21
4
TEVA PHARMACEUTICAL INDUSTRIES / Gianfranco Nazzi ownership change
8 Mar 21
4
TEVA PHARMACEUTICAL INDUSTRIES / Eliyahu Sharon Kalif ownership change
8 Mar 21
4
TEVA PHARMACEUTICAL INDUSTRIES / Hafrun Fridriksdottir ownership change
8 Mar 21
4
TEVA PHARMACEUTICAL INDUSTRIES / Eric Drape ownership change
8 Mar 21
4
TEVA PHARMACEUTICAL INDUSTRIES / Sven Dethlefs ownership change
8 Mar 21
Patents
GRANT
Utility
Training in dispensing a medicament
6 Apr 21
A medicament-free device (e.g., a smartphone device) for simulating a medicament dispenser may include a sensing device and a processor.
APP
Utility
Position-specific Asymmetric Deuterium Enriched Catecholamine Derivatives and Medicaments Comprising Said Compounds
1 Apr 21
Inventors: Rudolf-Giesbert ALKEN, Frank Schneider
GRANT
Utility
Aerosol device
30 Mar 21
The present invention provides an aerosol device for delivering a pharmaceutical formulation by inhalation via the mouth to the lungs or to the nostril in metered doses comprising: a pressurised aerosol canister including a vial containing a pharmaceutical formulation comprising an active ingredient, a propellant and, optionally, a co-solvent, the aerosol canister further comprising a metering valve having a valve stem; and an actuator for the aerosol canister, the actuator including a delivery outlet and a stem block, the stem block having a receptacle into which the valve stem of the metering valve of the aerosol canister is received and axially located and being displaceable relative to the vial of the aerosol canister to actuate the metering valve of the aerosol canister, a sump extending below the receptacle, the stem block further defining a discharge orifice arranged to direct the pharmaceutical formulation through the delivery outlet, a transfer tunnel having an input opening and an output opening through which a dispensed dose of the pharmaceutical formulation is able to pass from the sump to the discharge orifice, and a land length defining the distance from between the input opening and output opening, wherein the input opening and the output opening have cross-sectional areas of from 0.002 to 0.8 mm2 and the cross-sectional area of the input opening is smaller than the cross-sectional area of the output opening, and wherein the land length is from 0.5 mm to 10 mm.
APP
Utility
Crystalline Siponimod Fumaric Acid and Polymorphs Thereof
25 Mar 21
Disclosed crystalline Siponimod fumaric acid, solid state forms (polymorphs) thereof, processes for preparation thereof and pharmaceutical compositions thereof.
GRANT
Utility
Processes for the preparation of Niraparib and intermediates thereof
23 Feb 21
The present invention relates to novel procedures and novel intermediates useful in the synthesis of Niraparib or any salt thereof.
Transcripts
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
5 Aug 20
2020 Q1
Earnings call transcript
7 May 20
2019 Q4
Earnings call transcript
12 Feb 20
2019 Q3
Earnings call transcript
7 Nov 19
2019 Q2
Earnings call transcript
7 Aug 19
2019 Q1
Earnings call transcript
2 May 19
2018 Q4
Earnings call transcript
13 Feb 19
2018 Q3
Earnings call transcript
1 Nov 18
2018 Q2
Earnings call transcript
2 Aug 18
Reddit threads
The Fujiwhara Effect: Option Play on TEVA in Advance of their Imminent Opioid Trial
16 Apr 21
Daily General Discussion and spitballin thread - April 14, 2021
14 Apr 21
Healthcare Growth stocks
3 Apr 21
If your net worth is under 100k, changing spending habits may help more than you think
31 Mar 21
Time to Position for 2nd Quarter
28 Mar 21
Daily Plays - March 22, 2021
22 Mar 21
Daily General Discussion and spitballin thread - March 19, 2021
19 Mar 21
Big Tech faces ‘way more’ than 10% downside, all-star investor Rich Bernstein warns
18 Mar 21
Daily General Discussion and spitballin thread - March 17, 2021
17 Mar 21
What would you consider to be best value play currently in the pharmaceutical sector?
13 Mar 21